Bogsrud 2013.

Methods	6‐Week wash‐out period 4‐Week before‐and‐after study
Participants	41 men and women aged 18 to 75 years with hypercholesterolaemia Exclusion criteria: serious adverse events during previous statin therapy, liver or kidney failure, individuals taking concomitant medication that would interfere with the study Atorvastatin baseline TC: 7.17 mmol/L (277 mg/dL) Atorvastatin baseline LDL‐C: 5.18 mmol/L (200 mg/dL) Atorvastatin baseline HDL‐C: 1.49 mmol/L (57.6 mg/dL) Atorvastatin baseline TG: 1.67 mmol/L (148 mg/dL)
Interventions	Atorvastatin 10 mg/d
Outcomes	Per cent change from baseline at 4 weeks of serum TC, LDL‐C, HDL‐C and TG
Notes	SDs were imputed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Atorvastatin 10 mg/d; treatment intervention was analysed, and as no placebo group was included for comparison, assessment of random sequence generation is not applicable
Allocation concealment (selection bias)	Unclear risk	Atorvastatin 10 mg/d; treatment intervention was analysed, and as no placebo group was included for comparison, assessment of allocation concealment is not applicable
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Atorvastatin 10 mg/d; treatment intervention was analysed, and as no placebo group was included for comparison, blinding status is not applicable
Incomplete outcome data (attrition bias) All outcomes	Low risk	Data on all participants were reported
Selective reporting (reporting bias)	Low risk	All lipid parameters were measured
Other bias	Low risk	The study was funded by Pharma Nord ApS, which does not market statins of any kind